Beijing Biotech

This study tests a new treatment using donor immune cells (CAR-NK cells) that are designed to attack cancer cells based on specific markers found in each patient's tumor. About 60 adults with advanced solid tumors that have not responded to standard treatments will receive these …

This study tests a one-time treatment using a patient's own immune cells, modified to target and destroy specific cells causing lupus. It is for adults with severe lupus that has not improved with standard therapies. The goal is to see if this approach can safely control the dise…

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two markers on neuroblastoma cells. It is for children and young adults aged 1 to 21 whose cancer has come back or not responded to standard treatments. Participants first receive ch…

This study is testing a new type of CAR-T cell therapy that targets two different markers on cancer cells at the same time. It is for adults with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or not responded to other treatments. The goal is to se…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) that target two markers found on mesothelioma tumors. The therapy is given directly into the chest or abdomen. The trial aims to find the safest dose and see if it can shrink tumors or slow di…

This early-phase trial tests a new treatment for adults with glioblastoma or other high-grade gliomas that have come back after standard therapy. The treatment uses specially engineered immune cells (CAR-NK cells) that are designed to target two different markers on tumor cells a…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) that target specific markers on colorectal cancer cells. The goal is to see if these cells are safe and can shrink tumors in people with advanced or metastatic colorectal cancer who have run o…

This study tests a new treatment for people with advanced non-small cell lung cancer that has not responded to standard therapies. Participants receive specially designed natural killer (NK) immune cells that target two cancer-related proteins on their tumor cells. The goal is to…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) that target two cancer markers at once. It is for people with ovarian, peritoneal, or fallopian tube cancer that has come back or not responded to at least two prior treatments. The therapy is…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) to fight advanced breast cancer. About 60 adults with HER2-positive or triple-negative breast cancer that has spread or cannot be removed will receive cells tailored to their tumor's markers. …

This study tests a new treatment for adults with advanced solid cancers that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified to attack two cancer targets at once, chosen based on each tumor's unique markers. The goal is to impro…

This study tests a new treatment for adults with advanced liver cancer that has not responded to standard therapies. The treatment uses specially designed immune cells from a donor to target two proteins on cancer cells. The goal is to see if the treatment is safe and can shrink …

This early-stage trial tests a new treatment made from donor immune cells (CAR-NK cells) designed to attack two targets on bladder cancer cells. It is for adults with advanced bladder cancer that has not responded to standard therapies. The main goals are to check safety and see …

This early-phase study tests a new treatment for adults with glioblastoma or high-grade glioma that has come back after standard therapy. The treatment uses specially engineered natural killer (NK) cells designed to target two different markers on tumor cells at once, which may h…

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target specific markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have not responded to standard therapies. The goal is to se…

This early-stage trial tests a new treatment made from a person's own immune cells (NK cells) that are engineered to recognize and attack pancreatic cancer cells. The study includes 42 adults with advanced pancreatic cancer that has spread or cannot be removed by surgery. The goa…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) that target multiple markers on small cell lung cancer cells. The goal is to see if these cells are safe and can shrink tumors in adults whose cancer has returned or not responded to standard …

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two proteins found on stomach cancer cells. The therapy is given to adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. Th…

This study tests a new treatment for adults with advanced or metastatic clear cell kidney cancer that has not responded to standard therapies. The treatment uses specially engineered natural killer (NK) cells from a donor that are designed to target two proteins (CD70 and CAIX) o…